What are the latest figures on the prescription dermatological drugs market’s size and projected CAGR?
The prescription dermatological drugs market size has grown strongly in recent years. It will grow from $37.77 billion in 2024 to $40.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the rise in the prevalence of skin disorders, increase in awareness of skin health, growth in dermatology clinics, expanding geriatric population, rise in healthcare spending, and rise in R&D investments.
The prescription dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $52.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing prevalence of skin disorders, rising awareness of dermatological health, expanding telemedicine adoption for dermatology consultations, growing skin care aesthetics, enhanced insurance coverage for dermatological treatments, and increasing demand for personalized medicine and precision dermatology. Major trends in the forecast period include the development of targeted biologic therapies, the adoption of gene editing for skin conditions, advancements in drug delivery systems, the adoption of personalized treatments through genetic profiling, the adoption of topical medications with improved absorption, and the adoption of artificial intelligence to optimize drug formulations and treatment plans.
Get Your Free Sample of The Global Prescription Dermatological Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21262&type=smp
Which Market drivers have played a significant role in driving the prescription dermatological drugs market?
The increasing prevalence of dermatological conditions is expected to drive the growth of the prescription dermatological drugs market going forward. Dermatological conditions are disorders of the skin, hair, or nails, including eczema, psoriasis, and acne, which require medical treatment to manage symptoms effectively. The increasing prevalence of dermatological conditions is primarily due to the growing exposure to environmental pollutants, lifestyle changes, and rising stress levels. Prescription dermatological drugs play a crucial role in managing dermatological conditions by offering targeted treatments to alleviate symptoms and improve long-term skin health. For instance, in March 2022, Europe PubMed Central, a UK-based organization hosted by EMBL’s European Bioinformatics Institute for biomedical research works, reported that, in a study conducted across 27 European countries, approximately 43.35% of participants, equating to around 185 million individuals, experienced at least one skin condition, with fungal infections, atopic dermatitis, and acne being the most common. Therefore, the increasing prevalence of dermatological conditions is driving the growth of the prescription dermatological drugs market.
What are the key segments within the prescription dermatological drugs market?
The prescription dermatological drugs market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Retinoids, Calcineurin Inhibitors, Antifungal Agents, Antibiotics, Other Drug Classes
2) By Indication: Acne, Psoriasis, Dermatitis, Fungal Skin Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Retinoids: Topical Retinoids, Oral Retinoids
3) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors, Oral Calcineurin Inhibitors
4) By Antifungal Agents: Topical Antifungals, Oral Antifungals
5) By Antibiotics: Topical Antibiotics, Oral Antibiotics
6) By Other Drug Classes: Immunosuppressants, Phototherapy Agents
Order your report now for swift delivery
Which key players are shaping the prescription dermatological drugs market?
Major companies operating in the prescription dermatological drugs market are Pfizer Inc., Johnson & Johnson, Merck KGaA, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.
Which transformative trends will shape the prescription dermatological drugs market landscape?
Major companies operating in the prescription dermatological drugs market are focusing on developing innovative treatments, such as prurigo nodularis, to address unmet medical needs and offer more effective solutions for patients suffering from chronic and challenging skin conditions. Prurigo nodularis is a chronic skin condition characterized by the presence of intensely itchy, raised, and firm nodules or bumps on the skin. For instance, in September 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, partnered with Sanofi S.A., a France-based pharmaceutical company, and received approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab). This marks the first and only FDA-approved treatment for prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. The approval was granted based on clinical trials showing significant improvements in itch severity and skin lesions in patients treated with Dupixent compared to those receiving a placebo.
How do regional factors impact the prescription dermatological drugs market, and which region is the largest contributor?
North America was the largest region in the prescription dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription dermatological drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Prescription Dermatological Drugs Market Report 2025 Offer?
The prescription dermatological drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Prescription dermatological drugs refer to medications that are prescribed by healthcare providers to treat various skin conditions. They are used for managing issues such as acne, eczema, psoriasis, and other dermatological disorders, often containing active ingredients that require medical supervision.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21262
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
